ResearcherGuangzhou Medical UniversityActive in the last 2 years

Ling Qi

ORCID-verified (high confidence)As of 11 November 2026

Matched on ORCID iD 0000-0002-6275-3599; OpenAlex author ID A5100616382.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2024: 1 paper · 2025: none · 2026: 1 paper

Papers 2

Schisandrin B exhibits anti‑proliferative effects by inducing ferroptosis in pancreatic cancer. Last author DOI 10.3892/or.2026.9152 ↗
Eupalinolide B suppresses pancreatic cancer by ROS generation and potential cuproptosis. Last author DOI 10.1016/j.isci.2024.110496 ↗

Closest collaborators

The 3 strongest of 3 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Fengjin Li · 2 shared papers, 2024–2026
- Paper Schisandrin B exhibits anti‑proliferative effects by inducing ferroptosis in pancreatic cancer. DOI 10.3892/or.2026.9152 ↗
- Paper Eupalinolide B suppresses pancreatic cancer by ROS generation and potential cuproptosis. DOI 10.1016/j.isci.2024.110496 ↗
Jie Yang · 1 shared paper, 2024
- Paper Eupalinolide B suppresses pancreatic cancer by ROS generation and potential cuproptosis. DOI 10.1016/j.isci.2024.110496 ↗
Qingtian Huang · 1 shared paper, 2024
- Paper Eupalinolide B suppresses pancreatic cancer by ROS generation and potential cuproptosis. DOI 10.1016/j.isci.2024.110496 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.